Monte Rosa’s Bowen discloses initial GLUE equity stake
Monte Rosa Therapeutics, Inc. executive Matthew Bowen, Principal Accounting Officer, filed an initial ownership report showing direct holdings of common stock and multiple stock option awards.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
Monte Rosa Therapeutics, Inc. executive Matthew Bowen, Principal Accounting Officer, filed an initial ownership report showing direct holdings of common stock and multiple stock option awards. He reports 21,604 shares of common stock held directly, which includes 3,590 unvested restricted stock units that convert into shares as they vest.
Bowen also holds several stock options to buy common stock at exercise prices ranging from $5.71 to $23.99 per share, with expiration dates between 2031 and 2036. These options vest over time, often with 25% vesting on a stated date and the balance in 36 monthly installments, contingent on continued service.
Insider Trade Summary
9 transactions reported
Mixed
9 txns
Insider
Bowen Matthew
Role
Principal Accounting Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 43,025 contracts (Direct);
Common Stock — 21,604 shares (Direct)
Footnotes (8)
- F1. The amount reported in Column 2 includes 3,590 unvested restricted stock units ("RSUs") granted under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement.
- F2. This option is fully vested and exercisable.
- F3. 25% of this option vested and became exercisable on January 3, 2024, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
- F4. 25% of this option vested and became exercisable on January 1, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
- F5. 25% of this option vested and became exercisable on March 1, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
- F6. 25% of this option vested and became exercisable on January 2, 2026, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
- F7. 25% of this option shall vest and become exercisable on October 1, 2026, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
- F8. 25% of this option shall vest and become exercisable on January 2, 2027, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Direct common stock holdings: 21,604 shares
Unvested RSUs included: 3,590 RSUs
Option exercise price: $23.99 per share
+3 more
6 metrics
Direct common stock holdings
21,604 shares
Common Stock held directly as of Form 3
Unvested RSUs included
3,590 RSUs
Restricted stock units under 2021 Stock Option and Incentive Plan
Option exercise price
$23.99 per share
Stock option exercisable for 5,500 underlying shares, expiring 2031-10-31
Option exercise price
$13.41 per share
Stock option exercisable for 9,950 underlying shares, expiring 2032-02-29
Lowest option exercise price
$5.71 per share
Stock option exercisable for 3,698 underlying shares, expiring 2034-01-01
Largest option block
10,800 underlying shares
Stock option at $7.11 exercise price, expiring 2035-01-01
Key Terms
restricted stock units ("RSUs"), Stock Option (Right to Buy), exercise price, vesting, +1 more
5 terms
restricted stock units ("RSUs") financial
"includes 3,590 unvested restricted stock units ("RSUs") granted under the Issuer's 2021 Stock Option and Incentive Plan"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price": "7.1100""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"with the remainder vesting in 36 substantially equal monthly installments thereafter"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Form 3 regulatory
"INSIDER FILING DATA (Form 3)"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Matthew Bowen’s Form 3 filing for Monte Rosa Therapeutics (GLUE) show?
The Form 3 shows Matthew Bowen’s initial ownership in Monte Rosa Therapeutics, including 21,604 common shares and several stock option grants. It also notes 3,590 unvested RSUs that can convert into common stock as vesting conditions tied to continued service are met.
What stock options does Matthew Bowen hold in Monte Rosa Therapeutics (GLUE)?
Bowen holds several stock options to purchase Monte Rosa common stock with exercise prices from $5.71 to $23.99 per share. These options cover different underlying share amounts and have expiration dates from 2031 through 2036, providing potential future share acquisition if exercised.
How do Matthew Bowen’s RSUs in Monte Rosa Therapeutics (GLUE) work?
Bowen’s 3,590 RSUs each represent a contingent right to receive one Monte Rosa common share. They were granted under the 2021 Stock Option and Incentive Plan and convert into shares only as vesting and settlement occur, subject to his continued service with the company on specified vesting dates.
What are the vesting terms of Matthew Bowen’s Monte Rosa Therapeutics (GLUE) options?
Several Bowen option grants vest 25% on a specific initial date, with the remaining 75% vesting in 36 substantially equal monthly installments. Vesting is conditioned on his continued service with Monte Rosa Therapeutics on each vesting date, aligning long-term incentives with ongoing employment.
Does Matthew Bowen currently exercise any Monte Rosa Therapeutics (GLUE) options in this Form 3?
The Form 3 lists Bowen’s existing option and stock holdings but does not show option exercises or share sales. It focuses on his post-grant holdings, including vested and unvested options and RSUs, as of the reporting date, providing a baseline of his equity position with the company.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates